We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
- Authors
Bokemeyer, C; Bondarenko, I; Hartmann, J T; de Braud, F; Schuch, G; Zubel, A; Celik, I; Schlichting, M; Koralewski, P
- Abstract
The randomized phase II OPUS (Oxaliplatin and Cetuximab in First-Line Treatment of Metastatic Colorectal Cancer) study showed that tumor KRAS mutation status was predictive for outcome in patients receiving cetuximab plus FOLFOX-4 (oxaliplatin/5-fluorouracil/folinic acid) as first-line therapy for metastatic colorectal cancer (mCRC).
- Publication
Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Vol 22, Issue 7, p1535
- ISSN
1569-8041
- Publication type
Journal Article
- DOI
10.1093/annonc/mdq632